Rezolute (RZLT) Long-Term Debt Repayments (2012 - 2014)
Rezolute recorded quarterly Long-Term Debt Repayments of $167200.0 in Q2 2014, up 147.7% quarter-over-quarter from $67500.0 in Q1 2014.
Rezolute's Long-Term Debt Repayments history runs 2 years deep, the most recent figure standing at $167200.0 for Q2 2014.
- In Q2 2014, Long-Term Debt Repayments changed N/A year-over-year to $167200.0; the TTM figure through Jun 2015 stood at $234700.0 (changed 0.0% YoY), while the FY2022 annual figure was $16.0 million, up 6.75% from the prior year.
- Long-Term Debt Repayments came in at $167200.0 for Q2 2014 at Rezolute, up from $67500.0 in the prior quarter.
- In the past five years, Long-Term Debt Repayments ranged from a high of $167200.0 in Q2 2014 to a low of $35500.0 in Q1 2012.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Rezolute | 374.41 Mn | 374.41 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2014 | 167,200.00 |
| Jun 30, 2014 | 167,200.00 |
| Mar 31, 2014 | 67,500.00 |
| Mar 31, 2014 | 67,500.00 |
| Mar 31, 2012 | 35,500.00 |
| Mar 31, 2012 | 35,500.00 |